Kura Oncology Inc (NASDAQ:KURA) CFO Marc Grasso Sells 10,000 Shares

Kura Oncology Inc (NASDAQ:KURA) CFO Marc Grasso sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $29.00, for a total transaction of $290,000.00. Following the transaction, the chief financial officer now directly owns 7,898 shares in the company, valued at approximately $229,042. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Marc Grasso also recently made the following trade(s):

  • On Tuesday, September 8th, Marc Grasso sold 10,000 shares of Kura Oncology stock. The stock was sold at an average price of $26.00, for a total transaction of $260,000.00.
  • On Tuesday, August 25th, Marc Grasso sold 10,000 shares of Kura Oncology stock. The stock was sold at an average price of $23.00, for a total transaction of $230,000.00.

NASDAQ KURA opened at $29.00 on Wednesday. Kura Oncology Inc has a 12 month low of $6.35 and a 12 month high of $29.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 18.45 and a quick ratio of 18.45. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of -18.04 and a beta of 2.43. The company’s fifty day moving average price is $21.53 and its two-hundred day moving average price is $15.71.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.40) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.02. As a group, analysts anticipate that Kura Oncology Inc will post -1.66 EPS for the current year.

Several institutional investors have recently bought and sold shares of the company. Two Sigma Advisers LP lifted its position in shares of Kura Oncology by 2.9% in the 2nd quarter. Two Sigma Advisers LP now owns 249,100 shares of the company’s stock worth $4,060,000 after buying an additional 7,100 shares during the last quarter. Nuveen Asset Management LLC lifted its position in shares of Kura Oncology by 103.4% in the 2nd quarter. Nuveen Asset Management LLC now owns 787,976 shares of the company’s stock worth $12,844,000 after buying an additional 400,579 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Kura Oncology by 30.3% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 329,329 shares of the company’s stock worth $5,369,000 after buying an additional 76,668 shares during the last quarter. California State Teachers Retirement System lifted its position in shares of Kura Oncology by 54.3% in the 2nd quarter. California State Teachers Retirement System now owns 79,980 shares of the company’s stock worth $1,304,000 after buying an additional 28,149 shares during the last quarter. Finally, Great West Life Assurance Co. Can lifted its position in shares of Kura Oncology by 127.4% in the 2nd quarter. Great West Life Assurance Co. Can now owns 3,818 shares of the company’s stock worth $62,000 after buying an additional 2,139 shares during the last quarter. Institutional investors own 92.88% of the company’s stock.

KURA has been the subject of several recent research reports. Barclays increased their price objective on shares of Kura Oncology from $24.00 to $32.00 and gave the stock an “overweight” rating in a research report on Monday, August 31st. Deutsche Bank lowered their price target on shares of Kura Oncology from $28.00 to $24.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Kura Oncology in a report on Friday, May 29th. BidaskClub raised shares of Kura Oncology from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Finally, Zacks Investment Research lowered shares of Kura Oncology from a “buy” rating to a “hold” rating in a report on Wednesday, July 15th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Kura Oncology presently has a consensus rating of “Buy” and an average price target of $26.13.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Further Reading: Black Swan

Insider Buying and Selling by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.